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Introduction 
Despite the improved results seen in renal transplantation observed with the introduction 
of cyclosporine (eyA) immunosuppression in the 1980's, a finite number of grafts are still lost due 
to irreversible and ongoing rejection (1-3). Although the use of sequential induction therapy with 
antilymphocyte preparations followed by Cy A mitigates the incidence of initial first rejection 
episodes to a certain extent, even retreatment with high dose steroids and/or further anti-
lymphocyte therapy may be unsuccessful (4-6). These observations in clinical renal 
transplantation have stimulated interest in the development of novel drugs that may be useful in 
"rescuing" renal allografts failing these standard protocols. Tacrolimus is a novel macrolide 
immunosuppressant which has been used with encouraging results in primary renal transplantation 
(7, 8). This drug appears to have the additional advantage of permitting the tapering, and in some 
cases, cessation of steroid therapy allowing for tacrolimus monotherapy in up to 40% of patients 
(8). The efficacy of tacrolimus in primary renal transplantation led us to evaluate this agent for 
"rescue" of renal allografts undergoing intractable acute rejection which could not be reversed by 
the standard therapies available, including high dose steroids and antilymphocyte preparations (9, 
10). This report summarizes our experience with tacrolimus for salvage therapy of rejecting renal 
allografts under primary CyA immunosuppression. 
Materials and Methods 
Seventy-seven patients (mean age 33.3 ± 12.4 years) under primary CyA 
immunosuppression with ongoing biopsy-proven acute cellular rejection were converted to 
tacrolimus immunosuppression. The characteristics of the 77 patients are shown in Table 1. The 
majority of the patients (59) were primary transplant recipients; however, a significant number 
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(23%) had been re-transplanted. Fifty-two patients (68%) received cadaveric grafts and 25 (32%) 
living donor grafts. Four of the 77 patients received kidney-pancreas transplants and 1 kidney and 
pancreatic islet transplant. All of the patients had ongoing, biopsy-confirmed acute cellular 
rejection either with (n=20, 26%) or without (n=47, 61%) a vascular component of rejection at 
the time of conversion to tacrolimus. In addition, 10 patients (13 %) had rejection in grafts that 
had never functioned from the time of the transplant. The majority of the patients 
(n=64, 78%) were referred with their failing grafts from other institutions; the remainder (n=13, 
22%) were entered into this study early in this series from our own center (prior to our exclusive 
use oftacrolimus as a primary immunosuppressive agent in 1990). Baseline immunosuppression 
included CyA and prednisone in all patients, either with (n=22, 29%) or without (n=55, 71%) 
azathioprine as a third agent. Anti-rejection therapy administered to all patients included high 
dose bolus corticosteroids, and 61 patients (79%) also received at least 1 course of a monoclonal 
(OKT3) or polyclonal (ATG or AT GAM) antilymphocyte preparation. Tacrolimus was started 
only after the most recent biopsy ( <1 week) confirmed the presence of ongoing acute rejection 
and Doppler ultrasound and/or radionuclide study of the allograft had confirmed the absence of a 
technical cause for allograft dysfunction. Tacrolimus conversion was carried out as a simple 
switch ( "clean conversion") from CyA with no overlapping doses starting 12 hours following the 
last dose ofCyA, as previously described (10). Tacrolimus was given at 0.3 mg/kg/day orally in 
divided doses every 12 hours. Parenteral doses of 0.025 to 0.1 mg/kg/day overlapping with the 
first 1 to 4 days of oral therapy were also given to 16 patients. Monitoring of trough serum 
tacrolimus levels by ELISA (10) to achieve a 12 hour trough level of l.0 to 2.0 ng/ml was used 
for dosage adjustments. 
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Results 
Conversion from CyA to tacrolimus was deemed successful based on a return to baseline 
serum creatinine (SCR), and/or improvement on postconversion renal allograft biopsy, and/or 
freedom from dialysis if the patient was dialysis-dependent upon conversion. Of the 77 patients, 
successful rescue according to these criteria was achieved in 57 cases (74%) with a mean follow-
up of 16 months. Of 18 patients who were dialysis-dependent at the time of conversion to 
tacrolimus, 9 (50%) were successfully salvaged and have a mean SCRof2.3 mg/dl. Of the subset 
of 61 patients who received pre-conversion antilymphocyte preparations in an attempt to treat the 
ongoing rejection, success was achieved in 48 (79%). Successful conversion occurred in 37 of 52 
(73%) cadaveric graft recipients and in 20 of25 (80%) living donor recipients. Three of the four 
patients with combined kidney-pancreas grafts and the 1 kidney-pancreatic islet graft were 
rescued. The degree of success was influenced to a certain extent by the type of initial baseline 
immunosuppressive. Forty-five out of 55 (82%) of those patients initially receiving CyA-based 
triple therapy with azathioprine were salvaged compared with only 12/22 (55%) initially on CyA-
prednisone double therapy (p=0.03). In those patients successfully rescued, prednisone tapering 
was possible: the average pre-conversion prednisone dose of22.2 ± 7.2 mg/day was tapered to 
7.5 ± 5.6 mg/day, and 12 patients (21%) of the 57 with functioning grafts are currently on 
tacrolimus monotherapy. No patient is receiving more steroid post-conversion than pre-
conversion. Two patients had re-rejection episodes subsequent to initial successful rescue with 
tacrolimus. In one case, the SCR increased from 2.8 to 3.4 mg/dl 19 months following rescue and 
was treated successfully with an increased prednisone dose (7.5 to 15 mg/day) with a return to 
baseline SCR Another patient required a 1 gm bolus of methylprednisone 3 weeks after 
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tacrolimus conversion for a rejection episode (SCR increased from 2.2 tu 2.7 mg/dl) and 
continues to do well on 17.5 mg prednisone daily with a SCR of2.3 mg/dl. 
At long term followup following rescue (median = 42 months), 48 patients (62%) 
continue to have a functioning graft. There have been 9 late graft losses after initial successful 
rescue; 5 due to chronic rejection, 1 to noncompliance, and 3 to patient death. 
Discussion 
Even with triple and quadruple drug Cy A immunosuppression the incidence of graft loss 
due to intractable rejection continues to be a vexing problem for transplant physicians. The 
development of novel immunosuppressive drugs in the last 5 years has resulted in several of these 
agents entering into clinical trials in an attempt to improve the results of renal transplantation 
witnessed in the 1980's under CyA-based regimens. One of the most promising of these agents, 
tacrolimus, is currently in phase III clinical trials, has been shown to be safe and efficacious in 
trials of renaL hepatic, and thoracic transplantation. Several potential advantages oftacrolimus 
suggested by these studies include steroid-sparing effects while lacking some of the more 
undesirable side effects ofCyA (7-10). We have now demonstrated that an additional property of 
tacrolimus that is distinct from CyA is its ability to reverse ongoing rejection in renal allografts, 
even when agents as potent as antilymphocyte preparations have not been effective. The 
advantage of such an agent in the clinical armamentarium for renal transplantation is clear: the 
risks of excessive treatment with steroids and/or antilymphocyte preparations can be reduced or 
avoided. The specific cellular mechanisms by which tacrolimus acts in this regard are not clear, 
but are currently being investigated in our laboratory (11). Nevertheless, it is evident that trials 
comparing tacrolimus to the other more traditional agents used for rejection episodes (steroids, 
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OKT3, ATGAM) should be initiated to further elucidate the specific indications for the use of this 
promising drug for rescue of renal allograft rejection. 
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Table 1 
Cha.racteristics of77 Patients Converted to Tacrolimus for Ongoing Rejection 
No. Patients ( % ) 
Males 44 57% 
Females 33 43% 
Primary Transplants 59 77% 
Repeat Transplants 18 23% 
Cadaveric donor 52 68% 
Living donor 25 32% 
Maintenance Immunosuppression: 
Cy A + prednisone 55 71% 
Cy A + azathioprine + prednisone 22 29% 
Rejection Immunosuppression: 
High dose steroids alone 16 21% 
High dose steroids + 
OKT3/ ATG/ ATGAM 61 79% 
Biopsy at conversion to tacrolimus: 
Acute cellular rejection 47 61% 
Acute cellular + vascular rejection 20 26% 
Acute cellular rejection + primary nonfunction 10 13% 
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